Procept Biorobotics Corporation released an investor day presentation outlining its focus on expanding adoption of its Aquablation therapy for benign prostatic hyperplasia in the U.S. market. The company cited an estimated 40 million U.S. men living with BPH, about 400,000 annual BPH surgical procedures, and approximately 10 percent Aquablation penetration. It also reported more than 125,000 patients treated worldwide and a global installed base of more than 600 systems, and noted Category I reimbursement effective January 1, 2026. The presentation described commercial changes aimed at accelerating procedure growth, including a regional realignment and dedicated launch teams intended to standardize training, reimbursement, and patient education; the company said pilot accounts in Q4 2025 saw about a 50 percent reduction in time from purchase order to the first ten cases. It also discussed exploring leasing pilots and a targeted replacement strategy for capital equipment. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.
Comments